This activity is expired and is no longer available for CME credit.

CME

Practical Lipidology®: Volume 3, Number 2

Practical Lipidology®: Volume 3, Number 2

This activity is supported by an educational grant from Amgen

Overview

Author(s)/Faculty: Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FASPC, FCCP, FACC; Michael Miller , MD, FACC, FAHA ; Christie M. Ballantyne, MD; Alan S. Brown, MD, FACC, FAHA, FNLA; Robert S. Rosenson, MD, FACC, FACP, FAHA, FNLA, FESC
Source: Healio - Endocrinology Education Lab
Type: MultimediaArticles/Items: 7
Release Date: 9/1/2016Expiration Date: 9/1/2017
Credit Type: CMENumber of Credits: 1.25
Cost: FreeProvider: Vindico Medical Education

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing cardiovascular risk. Despite highly effective statin therapy, patients with persistently elevated LDL-cholesterol levels due to statin intolerance, inadequate therapeutic response, or familial hypercholesterolemia have important unmet clinical needs. Genetic insights into the mechanisms underlying the regulation of LDL-C levels have expanded potential molecular targets and led to the development of novel therapies. In response to new data and the approval of new agents, updated guidance was issued to help clinicians understand the role, as well as appropriate use of, non-statin therapies.

In this monograph, expert faculty will review LDL-C as a causal factor of atherosclerosis, new molecular targets for reducing LDL-C and risk of coronary heart disease CHD, as well as guidelines for risk assessment and dyslipidemia management.

CME Information

page 1 of 10